Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bionano Genomics Inc (NQ: BNGO )

0.9654 -0.0346 (-3.46%)
Streaming Delayed Price Updated: 2:46 PM EDT, May 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bionano Genomics Inc

< Previous 1 2 3 4 5 6 7 8 Next >
BNGO Stock: What Is Driving Bionano Genomics Higher Today?
Today, investors in Bionano Genomics and BNGO stock are cheering some positive clinical trial data around optical genome mapping. 
Via InvestorPlace
Bionano Genomics Remains Promising With Global Product Adoption
BNGO stock has been stuck in a range, but its next move should be to the upside based on Bionano's breakthrough genome mapping system. 
Via InvestorPlace
If You Invested $1,000 In BioNano Stock One Year Ago, Here's How Much You'd Have Now
Investors who have owned stocks in the last year have generally experienced some big gains. In fact, the SPDR S&P 500 (NYSE: SPY) total return over the last 12 months is 37.1... 
Via Benzinga
Topics Stocks
Exposures US Equities
The Price Is Right for BioNano Genomics Given Saphyr’s Potential
With its Saphyr system seeing adoption ramp up, the long-term growth potential for BNGO stock is considerable. 
Via InvestorPlace
Bionano Stock Will Soar as the Company’s Diagnostic System Catches On
As more payors reimburse labs for using Bionano's Saphyr device, the company's financial results will improve, lifting BNGO stock. 
Via InvestorPlace
Unusual Options Activity Insight: Bionano Genomics
Bionano Genomics (NASDAQ:BNGO) shares experienced unusual ... 
Via Benzinga
Faster and Better Clinical Outcomes Make the Case for Bionano Genomics
Bionano Genomics is mastering the science of genome mapping, while a reduced-price BNGO stock has a clear path forward for investors. 
Via InvestorPlace
Bionano Genomics, Inc (BNGO) Q2 2021 Earnings Call Transcript
BNGO earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Bionano’s Technology Is Interesting, But Its Earnings Are Uninspiring
Bionano could become a decent testing company within its niche. However, BNGO stock has run far ahead of the company's fundamentals. 
Via InvestorPlace
AMC Entertainment Tops Q2 Trends For Millenials And Gen Z, WISH Enters The Top 100
A quarterly report from Apex Clearing shows what the top owned stocks are among Millenials and Gen Z. Here is a look at the top holdings and the biggest movers from the first... 
Via Benzinga
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
Exposures Product Safety
Weak Fundamentals Prove There Is No Reason to Buy Bionano Genomics
Bionano Genomics is risky and its valuation does not justify its price. There is no compelling argument for a buy in BNGO stock. 
Via InvestorPlace
You’d Be Wrong to Paint Bionano Genomics Stock With the Meme-Stock Brush
With Bionano's disruptive tool, Saphyr, poised to revolutionize the DNA analysis sector, investors should definitely look to buy BNGO stock on its recent dip. 
Via InvestorPlace
Why Bionano Genomics, Invitae, and Opko Health Stocks Sank This Week
The market's pessimism about these diagnostics stocks appeared unrelated to company-specific news. 
Via The Motley Fool
Unusual Options Activity Insight: Bionano Genomics
Bionano Genomics (NASDAQ:BNGO) shares experienced unusual options activity on Friday. The stock price moved up to $6.71 following the option alert. Sentiment: BULLISH Option... 
Via Benzinga
Cramer Gives His Opinion On RadNet, Nano Dimension And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said RadNet Inc. (NASDAQ: RDNT) is a great situation and he likes the stock. BioNano Genomics Inc (NASDAQ: BNGO) is... 
Via Benzinga
Understanding Bionano Genomics's Unusual Options Activity
Shares of Bionano Genomics (NASDAQ:BNGO) saw some unusual options activity on Thursday. Following the unusual option alert, the stock price moved down to $7.05. Sentiment:... 
Via Benzinga
Bionano Genomics Stock Has Short-Term Opportunities
BNGO stock has established a reliable trading range. Even long-term investors can game it while they wait for their long-term reward. 
Via InvestorPlace
BNGO Stock: 2 Big Reasons Bionano Genomics Fans Should Be Cheering
Bionano Genomics (BNGO) stock is getting a boost on Monday from a couple of new pieces of news that traders will want to know. 
Via InvestorPlace
44 Stocks Moving In Monday's Mid-Day Session
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy. Marin Software... 
Via Benzinga
Wait for the Reddit Set to Sell Before Buying Bionano Stock
Genomics play BNGO stock may pay off down the road, but wait for a meme stock investor exodus before making it a buy 
Via InvestorPlace
Why Bionano Genomics Stock Is Trading Higher Today
BioNano Genomics Inc (NASDAQ: BNGO) shares are trading higher by 3.7% at $7.80 Monday morning after the company announced that it was added as a member of the U.S. small... 
Via Benzinga
Gene Editing Stocks: The Big News Lifting EDIT, BNGO, CRSP and NTLA Stocks
Gene editing stocks, led by NTLA stock, are powering higher on Monday following a landmark announcement by Intellia Therapeutics. 
Via InvestorPlace
Don’t Wait Around for a Short Squeeze on Bionano Genomics Stock
There are viable short-squeeze arguments available but BNGO stock is probably not one of them. 
Via InvestorPlace
Geographic Expansion Enables Healthy Diagnosis for Bionano Genomics
BNGO stock has a clear shot at revisiting its all-time high price 
Via InvestorPlace
The Owners of Bionano Stock Will Be Hurt by Dilution
BNGO stock looks decent until you dive deeper and understand what's really going on. The shares' outlook isn't good. 
Via InvestorPlace
Bionano Genomics: Did Reddit Squirrels Find a Nut?
BNGO stock has been pushed this year by both Wall Street pros and meme stock amateurs. Its optical genetic sequencing technique could make it a winner. 
Via InvestorPlace
Analyst Says Bionano Genomics Has 26% Upside: Should You Buy?
Before you buy some BNGO stock, you might want to check out some of the competition 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For June 16, 2021
Upgrades According to Piper Sandler, the prior rating for First Bancorp (NASDAQ: 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.